We began by exploring the difference between eradicating and controlling viruses. I described the importance of understanding viral behavior in public health strategies – for example, their varying incubation periods and evolutionary strategies and the implications for immunity and vaccination. The conversation touched on the challenges of vaccinating against viruses with short incubation periods like COVID-19.
You can find our entire conversation here.
For those wishing to explore further,
Henry I. Miller, MS, MD
Henry I. Miller, MS, MD, is the Glenn Swogger Distinguished Fellow at the American Council on Science and Health. His research focuses on public policy toward science, technology, and medicine, encompassing a number of areas, including pharmaceutical development, genetic engineering, models for regulatory reform, precision medicine, and the emergence of new viral diseases. Dr. Miller served for fifteen years at the US Food and Drug Administration (FDA) in a number of posts, including as the founding director of the Office of Biotechnology.
